Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
47 studies found for:    CAL101
Show Display Options
Rank Status Study
1 Suspended A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Idelalisib;   Drug: Ofatumumab
2 Completed Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber
Condition: Allergic Rhinitis
Interventions: Drug: CAL-101;   Drug: Placebo
3 Completed Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
Conditions: Indolent Non-Hodgkin's Lymphoma;   Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Marginal Zone Lymphoma
Intervention: Drug: Idelalisib
4 Withdrawn A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: GS-1101
5 Completed
Has Results
Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: Idelalisib
6 Active, not recruiting An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study
Conditions: Chronic Lymphocytic Leukemia;   Lymphoma, Non-Hodgkin
Intervention: Drug: Idelalisib
7 Recruiting Dose Optimization Study of Idelalisib in Follicular Lymphoma
Condition: Follicular Lymphoma
Intervention: Drug: Idelalisib
8 Active, not recruiting Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
Condition: Lymphoid Malignancies
Intervention: Drug: Idelalisib
9 Active, not recruiting
Has Results
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
Conditions: Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Lymphoplasmacytic Lymphoma;   Marginal Zone Lymphoma
Intervention: Drug: Idelalisib
10 Completed Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
Conditions: Chronic Lymphocytic Leukemia (CLL);   Lymphoma, Non-Hodgkin (NHL);   Acute Myeloid Leukemia (AML);   Multiple Myeloma (MM)
Intervention: Drug: CAL-101
11 Active, not recruiting Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Adults With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas or Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Indolent Non-Hodgkin Lymphoma;   Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia);   Marginal Zone Lymphoma
Interventions: Drug: Idelalisib;   Biological: Ofatumumab
12 Active, not recruiting Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Idelalisib
13 Recruiting Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)
Condition: Chronic Lymphocytic Leucemia
Interventions: Drug: Bendamustine;   Drug: GA101;   Drug: CAL-101
14 Recruiting Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis
Condition: Amyloidosis
Intervention: Drug: Idelalisib
15 Recruiting Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease
Condition: Myelofibrosis
Interventions: Drug: Idelalisib;   Drug: Ruxolitinib
16 Active, not recruiting Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Idelalisib;   Drug: Ofatumumab
17 Suspended Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: GS-1101
18 Terminated A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma (SLL)
Interventions: Drug: Idelalisib;   Drug: Rituximab
19 Terminated Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma
Condition: Pancreatic Ductal Adenocarcinoma
Interventions: Drug: Idelalisib;   Drug: Nab-paclitaxel;   Drug: mFOLFOX6
20 Completed
Has Results
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Idelalisib;   Drug: Rituximab;   Drug: Placebo to match idelalisib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.